Literature DB >> 25349002

Prostate cancer screening: going beyond the clinical evidence.

Murray Krahn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25349002      PMCID： PMC4216248          DOI： 10.1503/cmaj.141252

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  11 in total

1.  The next step in guideline development: incorporating patient preferences.

Authors:  Murray Krahn; Gary Naglie
Journal:  JAMA       Date:  2008-07-23       Impact factor: 56.272

2.  Recommendations on screening for prostate cancer with the prostate-specific antigen test.

Authors:  Neil Bell; Sarah Connor Gorber; Amanda Shane; Michel Joffres; Harminder Singh; James Dickinson; Elizabeth Shaw; Lesley Dunfield; Marcello Tonelli
Journal:  CMAJ       Date:  2014-10-27       Impact factor: 8.262

3.  Quality-of-life effects of prostate-specific antigen screening.

Authors:  Eveline A M Heijnsdijk; Elisabeth M Wever; Anssi Auvinen; Jonas Hugosson; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Arnauld Villers; Alvaro Páez; Sue M Moss; Marco Zappa; Teuvo L J Tammela; Tuukka Mäkinen; Sigrid Carlsson; Ida J Korfage; Marie-Louise Essink-Bot; Suzie J Otto; Gerrit Draisma; Chris H Bangma; Monique J Roobol; Fritz H Schröder; Harry J de Koning
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

4.  Construction of the Patient-Oriented Prostate Utility Scale (PORPUS): a multiattribute health state classification system for prostate cancer.

Authors:  M Krahn; P Ritvo; J Irvine; G Tomlinson; A Bezjak; J Trachtenberg; G Naglie
Journal:  J Clin Epidemiol       Date:  2000-09       Impact factor: 6.437

5.  Healthcare costs associated with prostate cancer: estimates from a population-based study.

Authors:  Murray D Krahn; Brandon Zagorski; Audrey Laporte; Shabbir M H Alibhai; Karen E Bremner; George Tomlinson; Padraig Warde; Gary Naglie
Journal:  BJU Int       Date:  2009-07-07       Impact factor: 5.588

6.  Patient and community preferences for outcomes in prostate cancer: implications for clinical policy.

Authors:  Murray Krahn; Paul Ritvo; Jane Irvine; George Tomlinson; Karen E Bremner; Andrea Bezjak; John Trachtenberg; Gary Naglie
Journal:  Med Care       Date:  2003-01       Impact factor: 2.983

Review 7.  Decision making and prostate cancer screening.

Authors:  Sara J Knight
Journal:  Urol Clin North Am       Date:  2014-02-28       Impact factor: 2.241

8.  Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.

Authors:  Amir Qaseem; Michael J Barry; Thomas D Denberg; Douglas K Owens; Paul Shekelle
Journal:  Ann Intern Med       Date:  2013-05-21       Impact factor: 25.391

9.  Why consider patients' preferences? A discourse analysis of clinical practice guideline developers.

Authors:  Antoine Boivin; Judith Green; Jan van der Meulen; France Légaré; Ellen Nolte
Journal:  Med Care       Date:  2009-08       Impact factor: 2.983

10.  Screening for prostate cancer. A decision analytic view.

Authors:  M D Krahn; J E Mahoney; M H Eckman; J Trachtenberg; S G Pauker; A S Detsky
Journal:  JAMA       Date:  1994-09-14       Impact factor: 56.272
View more
  6 in total

Review 1.  Update on age-appropriate preventive measures and screening for Canadian primary care providers.

Authors:  Tawnya Shimizu; Manon Bouchard; Cleo Mavriplis
Journal:  Can Fam Physician       Date:  2016-02       Impact factor: 3.275

2.  Prostate-specific antigen testing for prostate cancer screening: A national survey of Canadian primary care physicians' opinions and practices.

Authors:  Mitchell Geoffrey Goldenberg; Sean C Skeldon; Madhur Nayan; Yegappan Suppiah; Linda Chow; Elise Fryml; David Greenberg; Rajiv K Singal; S Larry Goldenberg
Journal:  Can Urol Assoc J       Date:  2017-11-01       Impact factor: 1.862

3.  Male Oncology Research and Education program for men at high risk for prostate cancer.

Authors:  J Lorentz; S K Liu; D Vesprini
Journal:  Curr Oncol       Date:  2018-04-30       Impact factor: 3.677

4.  Prediction of disease progression indicators in prostate cancer patients receiving HDR-brachytherapy using Raman spectroscopy and semi-supervised learning: a pilot study.

Authors:  Kirsty Milligan; Xinchen Deng; Ramie Ali-Adeeb; Phillip Shreeves; Samantha Punch; Nathalie Costie; Juanita M Crook; Alexandre G Brolo; Julian J Lum; Jeffrey L Andrews; Andrew Jirasek
Journal:  Sci Rep       Date:  2022-09-06       Impact factor: 4.996

5.  Getting (Along) With the Guidelines: Reconciling Patient Autonomy and Quality Improvement Through Shared Decision Making.

Authors:  Yan Xu; Philip S Wells
Journal:  Acad Med       Date:  2016-07       Impact factor: 6.893

6.  Can you un-ring the bell? A qualitative study of how affect influences cancer screening decisions.

Authors:  S Michelle Driedger; Gary Annable; Melissa Brouwers; Donna Turner; Ryan Maier
Journal:  BMC Cancer       Date:  2017-09-13       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.